Indapta Therapeutics snags $50m Series A

Indapta Therapeutics Inc, a natural killer cell therapy platform for the treatment of blood and solid tumor cancers, has raised over $50 million in Series A financing.

To view this content, you need to sign in.


You should only be asked to sign in once. Not the case? Click here


Register now to access this content and more for free.

Share this